Thomas Joseph Povsic

Journal Article Eur Heart J · December 16, 2024 BACKGROUND AND AIMS: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days vs. placebo after acut ... Full text Link to item Cite

Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.

Journal Article J Am Coll Cardiol · June 4, 2024 BACKGROUND: The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. OBJ ... Full text Link to item Cite

Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.

Journal Article N Engl J Med · May 2, 2024 BACKGROUND: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk o ... Full text Link to item Cite

View All Publications

Recent Grants

A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Subjects with Angina Pectoris Secondary

Clinical TrialPrincipal Investigator · Awarded by XyloCor Therapeutics · 2019 - 2024

Direct Administration of AdVEGF-All6A+ LOI

ResearchPrincipal Investigator · Awarded by XyloCor Therapeutics · 2020 - 2023

DREAM-HF

Clinical TrialPrincipal Investigator · Awarded by Mesoblast International Sarl · 2014 - 2021

View All Grants

Education, Training & Certifications

Harvard University · 1995 M.D.